NCT04055376Active, not recruiting
Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
In this trial, the safety and effect of daily exposure to light and sound stimulation on people with mild Alzheimer's Disease (AD) will be studied. COVID-19 Amendment: Due to the ongoing suspension of all in-person humans subject research across MIT in response to the COVID-19 pandemic, all enrolled participants who have not completed their 6-month visit will have their visit postponed to 9 months with a follow up at 18 months. Subjects who have completed their 6-month visit will still be instructed to continue and return at Month 12 for an evaluation. OPTIONAL: If the subject would like to come in for an evaluation between Month 9 and 18, we will invite participants to come on Month 12 to complete cognitive testing and EEG.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 5 Aug 2019
- Start date
- 14 Aug 2019
- Primary completion date
- 15 Jan 2027
- Lead sponsor
- Massachusetts Institute of Technology
- Diseases
- Alzheimer disease
- NCT number
- NCT04055376
What you commit to
- Study type: Interventional
- Participants enrolled: 15
- From 14 Aug 2019 to the primary completion date, 15 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).
- Active treatment with one or more anti-epileptic agent.
- Active treatment with one or more psychiatric agent (e.g. antidepressants, antipsychotics, etc).
Other illness
- Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.
- Subjects with history of seizure or epilepsy within the past 24 months.
- Subjects who have had a stroke within the past 24 months.
- Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator.
- Subjects who have profound hearing or visual impairment.
Other
- Subjects who do not have healthcare.
- Subjects with clinically significant suicide risk and/or suicide attempt in the past 12 months.
- Subjects with behavioral problems such as aggression/agitation/impulsivity that might interfere with their ability to comply with protocol.
- Subjects diagnosed with migraine headache.
- Subjects who have a life expectancy of less than 24 months.
- Subjects who are pregnant.
Who the study is looking for
- Subject is between the ages of 50 - 100.
- Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19 -26.
- Subject is willing to sign informed consent document.
- If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent.
- Subjects whose primary residence is within 2 hours of Boston
- Able to complete the 1st month of at home stimulation at their primary residence; if subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.
Age in the registry: 50 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts Institute of Technology Coordinator of this site? Confirm its status | Cambridge | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.